ME Therapeutics Holdings Company Description

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology.

Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer.

The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.

ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

ME Therapeutics Holdings Inc.

Country	Canada
Founded	2014
Industry	Biotechnology
Sector	Healthcare
CEO	Salim Dhanji

Contact Details

Address: 177 Robson Street Vancouver, British Columbia V6B 0N3 Canada
Phone	236-516-7714
Website	metherapeutics.com

Stock Details

Ticker Symbol	METX
Exchange	Canadian Securities Exchange
Reporting Currency	CAD
SIC Code	2836

Key Executives

Name	Position
Salim Dhanji	Chief Executive Officer and Director
Salim Dhanji Ph.D.	Chief Executive Officer and Director
Quinn Martin C.A., CPA	Chief Financial Officer
Jamil Kassam	Corporate Secretary